All News
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.
Read Article
How Often Do You Monitor MTX? (6.16.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
Read Article
ACR Concerned with MedPAC’s Cutting Part B Reimbursement
The American College of Rheumatology (ACR) today expressed disappointment that the Medicare Payment Advisory Commission (MedPAC) has recommended yet another cut to physician reimbursement for infusing life-altering treatments as part of its June 2023 Report to the Congress: Medicare and the Healt
Read Article
Higher Genetic Loads Linked to Worse Systemic Lupus
A Korean study of a large systemic lupus erythematosus (SLE) cohort shows by genomic analysis, that higher weighted genetic risk scores (wGRS) is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.
Read Article
Why Depression Screening Should be Mandatory at Each Visit
Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015.
Read Article
High Mortality Rates with Depression in Rheumatoid Arthritis
A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).
Read Article
Diagnostic Yield of Cranial and Large Vessel Imaging in GCA
Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA).
Read Article
EULAR Offers Tips on Psoriasis Progression to PsA
Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).
Read Article
Biosimilars Match Biologic Originators in Rheumatoid Arthritis
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Read Article
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Read Article
EULAR 2023 Notes from Milan (6.09.2023)
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Read Article
Clinically suspect arthralgias: justified or artefact?
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
Read Article
EULAR 2023 – Day 3 Report
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Read Article
EULAR 2023 – Day 2 Report
Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.
Read Article
EULAR 2023 – Day 1 Report
EULAR 2023 launched today to crowds of attendees. The opening Plenary session and presidential address by Dr.
Read Article
Aurelie Najm AurelieRheumo ( View Tweet)
